DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Prostate Cancer | Access and Reimbursement | Physician Dispensing of Oral Oncolytics in Prostate Cancer | US | 2018
MARKET OUTLOOK The increase in oral oncolytics has fueled an increase in physician dispensing of drugs either from the office or from a pharmacy owned by the practice or hospital, as allowed by…
Multiple Myeloma | Unmet Need | First-Line Transplant-Ineligible Multiple Myeloma | US/EU | 2018
Market Outlook The most important clinical distinction in the first-line treatment of multiple myeloma is determining whether the patient is eligible to undergo autologous stem-cell…
Spinal Muscular Atrophy | Niche & Rare Disease Landscape and Forecast | US/EU5 | 2018
Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by progressive muscle weakness due to the loss of anterior horn motor neurons. Nearly all cases of SMA are caused by…
Systemic Lupus Erythematosus | Current Treatment: Physician Insights | Systemic Lupus Erythematosus (Excluding Active Lupus Nephritis and Severe CNS Manifestations) | US | 2018
MARKET OUTLOOK SLE is an autoimmune disease characterized by varied symptoms ranging from general fatigue to serious organ manifestations. Options available to treat SLE are limited, with…
Psoriatic Arthritis | Emerging Therapies | Xeljanz (tofacitinib) | US | Wave 2 | 2018
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-…
